[The efficacy and safety of the reducing dose HAA regimen as induction chemotherapy in previously untreated elderly patients aged 60-69 years with acute myeloid leukemia]

Zhonghua Xue Ye Xue Za Zhi. 2014 Sep;35(9):845-7. doi: 10.3760/cma.j.issn.0253-2727.2014.09.014.

[Article in Chinese]

Authors

Peipei Ye¹, Feifei Chen¹, Qitian Mu¹, Wenyuan Mai¹, Haitao Meng¹, Wenbin Qian¹, Hongyan Tong¹, Jian Huang¹, Yin Tong¹, Zhimei Chen¹, Jiyu Lou¹, Yungui Wang¹, Wanmao Ni¹, Jie Jin¹

Affiliation

¹ Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.

PMID: 25246257
DOI: 10.3760/cma.j.issn.0253-2727.2014.09.014

No abstract available

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Induction Chemotherapy
Leukemia, Myeloid, Acute / drug therapy*
Middle Aged